SCHEMBL24664372

SCHEMBL24664372

CC(C)n1cc(-c2nc(Nc3ccc(N4CCN(C5CCN(C)CC5)CC4)cc3)ncc2F)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 3/20 0.55
▸ JAK2 O60674 11/20 0.54
▸ FLT3 P36888 8/20 0.54
▸ MAP4K1 Q92918 1/20 0.50
▸ JAK1 P23458 5/20 0.49
▸ JAK3 P52333 5/20 0.49
▸ CDK6 Q00534 5/20 0.48
▸ CDK4 P11802 4/20 0.48
▸ CDK2 P24941 3/20 0.48
▸ CCNA2 P20248 1/20 0.48
▸ TYK2 P29597 4/20 0.47
▸ KCNH2 Q12809 2/20 0.47
▸ PIK3CD O00329 1/20 0.47
▸ CCNB2 O95067 2/20 0.47
▸ CDK1 P06493 2/20 0.47
▸ CCNB1 P14635 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ CDK5R1 Q15078 2/20 0.47
▸ CCNB3 Q8WWL7 2/20 0.47
▸ CCNT1 O60563 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24664303 0.91 CSF1R (0.63) CSF1RJAK2FLT3MAP4K1JAK1
SCHEMBL24664281 0.89 JAK2 (0.61) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL29607208 0.89 JAK2 (0.61) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL24663800 0.82 CDK6 (0.68) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL24664300 0.81 CDK2 (0.59) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL24664426 0.80 CDK6 (0.67) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL29606969 0.80 EGFR (0.55) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL29608982 0.80 CDK6 (0.67) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL24664306 0.80 EGFR (0.55) CSF1RJAK2FLT3JAK1JAK3
SCHEMBL24663775 0.77 MYLK4 (0.50) CSF1RJAK2FLT3JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114423750-B 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof 成都赜灵生物医药科技有限公司 2024-04-19 — — CN disclosed
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2022-09-22 — — US disclosed
CN-114423750-A 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2022-04-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JAK2, FLT3, JAK1 CSF1R 91/4885JAK2 1/4885FLT3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback